Altimmune (STU:3G0) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3G0 Altimmune Inc STU:3G0
34 GF Score
Price €2.67
GF Value €0.28
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Altimmune FFO per Share?

FFO per Share only applies to REITs.

STU:3G0
34GF Score
Altimmune Inc STU:3G0
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Altimmune (STU:3G0) Overvalued in 2026?

Based on GuruFocus' analysis, Altimmune stock appears to be overvalued. The current stock price of €2.67 is trading 851.8% above its estimated GF Value™ of €0.28. GuruFocus considers Altimmune to be Significantly Overvalued.

Key valuation signals for STU:3G0:

  • FFO per Share:
  • GF Value™: €0.28 vs. price of €2.67 (851.8% above fair value)
  • GF Score™: 34/100 with 2 warning signs

No single metric tells the full story. See the STU:3G0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Altimmune Business Description

Other Exchanges ALT:USAALT1:Mexico0A4C:UK
Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
34GF Score

Get the complete analysis for STU:3G0

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.67
Price
€0.28
GF Value